Sean Milligan, MD
Neurology · Amarillo, TXNPI 1861438061
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $448,801 of the $579,662 with a category attached, or 77.4%. 56 manufacturers reported payments, led by Biogen at 53.8% of the total. Reporting peaked in 2019 at $136,990 and has fallen 51.3% since, to $66,681 in 2025. Among neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,613 payments — averaging $359.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$312K
- AstraZeneca$170K
- AbbVie$38K
- Amgen$21K
- Bristol Myers Squibb$15K
- E.r. Squibb & Sons, L.L.C.$9K
- plus $15K from 50 others
What the payments were for
- Consulting fees$35,3186%
- Speaking & faculty fees$448,80177%
- Travel & lodging$73,67913%
- Food & beverage$21,7374%
- Education$1280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$579,662 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 67 | $682,387 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 27 | $414,592 |
| VumerityDiroximel Fumarate | 36 | $303,374 |
| TysabriNatalizumab | 36 | $299,977 |
| NourianzIstradefylline | 59 | $170,318 |
| IngrezzaValbenazine Tosylate | 19 | $149,040 |
| AustedoDeutetrabenazine | 21 | $127,771 |
| TecfideraDimethyl Fumarate | 13 | $123,397 |
| BetaseronInterferon Beta-1b | 13 | $119,482 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $115,092 |
| BriviactBrivaracetam | 78 | $114,404 |
| RytaryCarbidopa/Levodopa | 115 | $107,512 |
| QuliptaAtogepant | 51 | $58,173 |
| NeuproRotigotine | 47 | $50,586 |
| VimpatLacosamide | 35 | $42,892 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Tysabri, Tecfidera | $311,613 | $726,74885 claims |
| PfizerOctagam, Nurtec Odt | $600 | $715,03891 claims |
| UCB, Inc.Briviact, Neupro, Vimpat | $415 | $207,881160 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $474 | $170,97031 claims |
| Kyowa Kirin, Inc.Nourianz | $5,229 | $170,31859 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $473 | $127,77121 claims |
| BayerBetaseron | $28 | $119,48213 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $123 | $112,451139 claims |
| AbbVieQulipta, Ubrelvy | $38,498 | $75,08062 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr | $433 | $32,22635 claims |
| SK Life Science, Inc.Xcopri | $169 | $20,69718 claims |
| Axsome Therapeutics, Inc.Auvelity | $168 | $15,66015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 neurology providers in Texas.
Other neurology in Amarillo
- Ann BassSan Antonio$1.7M
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Benjamin GreenbergDallas$773K
- Annette OkaiPlano$730K
- Waleed El-FekyDallas$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.